is the fda banning compounded tirzepatide Banned? Latest Rules FDA Ban on Compounded GLP-1

And you know when it's done when you hear the second click

The existing evidence base does not establish tirzepatide as a disease-modifying therapy for Hashimoto's thyroiditis or as a treatment that directly addresses the autoimmune pathophysiology underlying the condition

Critical Considerations: This schedule is purely theoretical and not based on clinical evidence Individual tolerance varies dramaticallysome may not tolerate even these conservative doses Maximum combined doses would likely need to remain below monotherapy maximums (perhaps 2.4 mg cagrilintide + 8 mg retatrutide as absolute ceiling) Medical supervision would be essential throughout any such protocol Alternative Approach: Sequential Rather Than Concurrent An arguably safer alternative to simultaneous cagrilintide dosage with retatrutide administration involves sequential optimization: Optimize one compound first Reach stable, effective dose of either cagrilintide or retatrutide Assess response Evaluate metabolic effects over 12-16 weeks Introduce second compound Only if additional effects are needed Ultra-gradual second titration Even slower escalation of the added compound Continuous reassessment Regular evaluation of whether combination provides benefits beyond monotherapy This approach provides clearer attribution of effects and side effects to specific compounds, though it significantly extends the overall timeline

Glycemic Control There is no question regarding the efficacy of GLP1 receptor agonists in achieving good glycemic control